Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
The anti-nonGal xenoantibody response to alpha1,3-galactosyltransferase gene knockout pig xenografts Harnden I; Kiernan K; Kearns-Jonker MCurr Opin Organ Transplant 2010[Apr]; 15 (2): 207-11PURPOSE OF REVIEW: Anti-nonGal xenoantibodies are a major barrier to the survival of genetically modified porcine xenografts. This review summarizes the contribution of anti-nonGal xenoantibodies to the activation of porcine endothelial cells and graft rejection, and further provides an update on recent advancements in defining the unique features of anti-nonGal xenoantibody structure. RECENT FINDINGS: Anti-nonGal xenoantibodies pre-exist at low levels in humans and nonhuman primates, and are notably absent in neonates. Exposure of nonhuman primates to alpha1,3-galactosyltransferase gene knockout endothelial cells initiates an induced xenoantibody response that is restricted and encoded by the germline immunoglobulin heavy chain gene IGHV3-21. The target xenoantigen remains undetermined, but several candidate targets have been proposed, including carbohydrate xenoantigens. New advancements in molecular modeling provide insight on the mechanism by which xenoantibodies bind to structurally related carbohydrates. SUMMARY: Genetic manipulation of porcine donors has significantly prolonged the survival of grafts placed into nonhuman primate recipients, but anti-nonGal xenoantibodies and thrombosis limit the ability of these grafts to function on a long-term basis. Recent developments defining pre-existing anti-nonGal xenoantibody levels, the restriction in the anti-nonGal xenoantibody response and the identification of key sites defining xenoantibody-carbohydrate interactions now provide the information necessary to develop new approaches to preventing xenoantibody-mediated rejection.|*Gene Knockout Techniques[MESH]|*Graft Survival/genetics[MESH]|*Transplantation Tolerance/genetics[MESH]|Amino Acid Sequence[MESH]|Animals[MESH]|Animals, Genetically Modified[MESH]|Antibodies, Heterophile/chemistry/*immunology[MESH]|Antigens, Heterophile/immunology[MESH]|Endothelial Cells/*immunology[MESH]|Galactosyltransferases/*deficiency/genetics/immunology[MESH]|Genes, Immunoglobulin Heavy Chain[MESH]|Graft Rejection/genetics/*immunology/pathology[MESH]|Immunity, Humoral[MESH]|Molecular Sequence Data[MESH]|Species Specificity[MESH]|Swine[MESH]|Transplantation, Heterologous/*immunology[MESH]|Trisaccharides/immunology[MESH] |
